[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:dermatomyositis":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":195,"states":196},"Dermatomyositis",30,25,[8,16,23,30,36,42,48,54,60,67,73,79,86,92,98,104,109,115,121,127,133,139,145,151,157,162,169,175,181,188],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06455449","A Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)",[12],"Phase 3","RECRUITING","2026-08-26T02:17:22.949982Z","2026-05-05T02:43:29.133695Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT06298019","Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis",[20],"Phase 1","2026-08-26T02:15:01.639696Z","2026-05-05T02:43:28.294101Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":28,"content_modified":29},"NCT06857240","Topical Ruxolitinib Cream for Refractory Cutaneous Dermatomyositis",[27],"Phase 2","2026-08-26T02:15:36.077529Z","2026-05-05T02:43:27.604479Z",{"nct_id":31,"title":32,"phases":33,"status":13,"updated_at":34,"content_modified":35},"NCT07486869","Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study",[27],"2026-08-26T02:16:16.169331Z","2026-05-05T02:43:27.250331Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT07111065","FAST for DM - Fatty Acid Supplementation Trial (FAST) for Dermatomyositis (DM)",[27],"2026-08-26T02:19:15.498463Z","2026-05-05T02:43:26.915388Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT07391605","Descartes-08 in Autoantibody Myositis",[27],"2026-08-26T02:17:18.747857Z","2026-05-05T02:43:26.907623Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT06698796","A Study to Understand How the Study Medicine Dazukibart Works in People With Idiopathic Inflammatory Myopathies",[12],"2026-08-26T02:16:47.762107Z","2026-05-05T02:35:31.904601Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT05895786","A Study to Understand How the Study Medicine (PF-06823859) Works in People With Active Idiopathic Inflammatory Myopathies [Dermatomyositis (DM) and Polymyositis (PM)]",[12],"2026-08-26T02:18:47.742071Z","2026-05-05T02:35:31.903073Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":65,"content_modified":66},"NCT07089121","Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders",[64],"Phase 1\u002FPhase 2","2026-08-26T02:16:38.897933Z","2026-05-05T02:43:27.171088Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT06672822","Intralesional Injection of STS in Treatment of Calcinosis",[27],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:26.748851Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT06371417","Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)",[20],"2026-08-26T02:19:24.527214Z","2026-07-24T01:27:14.904319Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":84,"content_modified":85},"NCT06154252","RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy",[83],"Phase 2\u002FPhase 3","2026-08-26T02:18:36.226508Z","2026-05-05T02:43:27.760583Z",{"nct_id":87,"title":88,"phases":89,"status":13,"updated_at":90,"content_modified":91},"NCT07138898","Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty",[27],"2026-08-26T02:16:54.876240Z","2026-05-05T02:43:27.643948Z",{"nct_id":93,"title":94,"phases":95,"status":13,"updated_at":96,"content_modified":97},"NCT03816345","Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO",[20],"2026-08-26T02:16:10.529598Z","2026-05-05T02:43:26.680299Z",{"nct_id":99,"title":100,"phases":101,"status":13,"updated_at":102,"content_modified":103},"NCT02945345","Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)",[],"2026-08-26T02:16:12.203827Z","2026-05-13T02:55:06.103545Z",{"nct_id":105,"title":106,"phases":107,"status":13,"updated_at":77,"content_modified":108},"NCT05738824","Natural History of Inflammatory Muscle Diseases",[],"2026-07-05T05:32:16.809778Z",{"nct_id":110,"title":111,"phases":112,"status":13,"updated_at":113,"content_modified":114},"NCT06037187","Coagulopathy of Immunodermatologic Diseases",[],"2026-08-26T02:15:00.557154Z","2026-05-13T02:55:06.403350Z",{"nct_id":116,"title":117,"phases":118,"status":13,"updated_at":119,"content_modified":120},"NCT00017914","Adult and Juvenile Myositis",[],"2026-08-26T02:19:04.543908Z","2026-05-13T02:55:06.027743Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT01422694","Natural History and Development of Spondyloarthritis",[],"2026-08-26T02:18:15.214990Z","2026-07-19T19:36:05.096286Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT07403188","A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101",[],"2026-08-26T02:16:00.194860Z","2026-05-13T02:55:06.700539Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT07374107","MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)",[],"2026-08-26T02:16:41.943926Z","2026-05-13T02:55:06.697864Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":143,"content_modified":144},"NCT06339957","Rheumatology Diet Study",[],"2026-08-26T02:19:09.651016Z","2026-05-13T02:55:06.482572Z",{"nct_id":146,"title":147,"phases":148,"status":13,"updated_at":149,"content_modified":150},"NCT04402086","Rheumatology Patient Registry and Biorepository",[],"2026-08-26T02:18:39.640967Z","2026-05-13T02:55:06.248878Z",{"nct_id":152,"title":153,"phases":154,"status":13,"updated_at":155,"content_modified":156},"NCT03276923","Maternal Autoimmune Disease Research Alliance (MADRA) Registry",[],"2026-08-26T02:18:00.873391Z","2026-05-13T02:55:06.121380Z",{"nct_id":158,"title":159,"phases":160,"status":13,"updated_at":149,"content_modified":161},"NCT01276470","Environmental Risk Factors for the Anti-synthetase Syndrome",[],"2026-05-13T02:55:06.071016Z",{"nct_id":163,"title":164,"phases":165,"status":166,"updated_at":167,"content_modified":168},"NCT06568783","Evaluation of Patients With Refractory Dermatomyositis Using [18F] FAPI-74 PET\u002FMRI Imaging",[27],"NOT_YET_RECRUITING","2026-08-26T02:18:06.247899Z","2026-05-05T02:43:27.568973Z",{"nct_id":170,"title":171,"phases":172,"status":166,"updated_at":173,"content_modified":174},"NCT07729995","BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease",[20],"2026-08-26T02:15:03.757872Z","2026-07-30T01:46:14.459181Z",{"nct_id":176,"title":177,"phases":178,"status":166,"updated_at":179,"content_modified":180},"NCT06999109","Teams Engaged in Accessible Mental Health Interventions for Lupus Erythematosus and Dermatomyositis Stress",[],"2026-08-26T02:19:30.857183Z","2026-07-05T05:32:16.722943Z",{"nct_id":182,"title":183,"phases":184,"status":185,"updated_at":186,"content_modified":187},"NCT05979441","A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy",[12],"ENROLLING_BY_INVITATION","2026-08-26T02:15:42.447052Z","2026-06-16T05:54:08.093063Z",{"nct_id":189,"title":190,"phases":191,"status":192,"updated_at":193,"content_modified":194},"NCT06665256","Phase 2 Study of Rapcabtagene Autoleucel in Myositis",[27],"ACTIVE_NOT_RECRUITING","2026-08-03T02:14:31.240767Z","2026-05-05T02:43:28.530829Z",[],[197,201,204,207,210,214,218,222,225,228,232,236,240,243,246,250,253,256,259,262,265],{"state":198,"count":199,"slug":200},"Maryland",10,"maryland",{"state":202,"count":199,"slug":203},"North Carolina","north-carolina",{"state":205,"count":199,"slug":206},"Pennsylvania","pennsylvania",{"state":208,"count":199,"slug":209},"Texas","texas",{"state":211,"count":212,"slug":213},"California",9,"california",{"state":215,"count":216,"slug":217},"Florida",8,"florida",{"state":219,"count":220,"slug":221},"Massachusetts",7,"massachusetts",{"state":223,"count":220,"slug":224},"New York","new-york",{"state":226,"count":220,"slug":227},"Ohio","ohio",{"state":229,"count":230,"slug":231},"Georgia",6,"georgia",{"state":233,"count":234,"slug":235},"Illinois",5,"illinois",{"state":237,"count":238,"slug":239},"Arizona",4,"arizona",{"state":241,"count":238,"slug":242},"Connecticut","connecticut",{"state":244,"count":238,"slug":245},"Kansas","kansas",{"state":247,"count":248,"slug":249},"Colorado",3,"colorado",{"state":251,"count":248,"slug":252},"District of Columbia","district-of-columbia",{"state":254,"count":248,"slug":255},"Michigan","michigan",{"state":257,"count":248,"slug":258},"Missouri","missouri",{"state":260,"count":248,"slug":261},"Oregon","oregon",{"state":263,"count":248,"slug":264},"Utah","utah",{"state":266,"count":248,"slug":267},"West Virginia","west-virginia"]